Catalent Pharma Solutions Extends Development and Analytical Solutions Capabilities in Swindon, UK

Somerset, NJ – March 22, 2012 — Catalent Pharma Solutions today announces the completion of new Development and Analytical Solutions’ laboratories at its facility in Swindon, UK. From this new laboratory suite, Catalent will offer expert analytical testing, development support and regulatory services to pharmaceutical and biopharmaceutical companies. The laboratory suite incorporates expanded, state-of-the-art facilities for the storage and testing of controlled and cytotoxic substances.

Catalent’s new Swindon laboratories offer a comprehensive range of development and analytical services. These services include European import testing, Qualified Person (QP) and regulatory consulting services, methods development, and microbial, sterility and stability testing for a range of advanced dose forms including for inhaled and orally administered substances.

“This additional capacity, coupled with our international network, means Catalent can offer an unparalleled range and scale of services to the development and testing of large and small molecules,” commented Graeme Lowe, Director of Analytical Solutions for Catalent in Swindon.

“The enhanced facilities here in Swindon are complimented by Catalent’s acquisitions of Aptuit’s Clinical Trials Supply business and the full ownership of the Eberbach softgel facility. We are now offering a broader range of pharmaceutical and biopharmaceutical testing services from five locations in the US, UK and Germany. We have the expertise and the global reach to help our customers bring more products to market faster,” said Christine Dolan, Vice President and General Manager of Catalent’s Development and Analytical Solutions.

About Catalent

From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has the deepest expertise, the broadest offerings and the most unique technologies in the industry. With over 75 years of experience, Catalent helps customers get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging solutions. Catalent employs approximately 9,400 people at 29 facilities worldwide and in fiscal year 2011 generated more than $1.6 billion in annual revenue. Catalent is headquartered in Somerset, NJ. For more information, visit www.catalent.com. more products. better treatments. reliably supplied.™

Media Contacts:

Christopher Halling

T +44 (0) 7580 041073

chris.halling@catalent.com

Patricia McGee

T +1 (732) 537 6407

patricia.mcgee@media.com